FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2067204905> ?p ?o ?g. }

• W2067204905 endingPage "147" @default.
• W2067204905 startingPage "143" @default.
• W2067204905 abstract "Objective.Irinotecan (CPT-11) is a DNA topoisomerase I inhibitor which has shown activityin vitroagainst several cancer cell lines and some promising clinical responses in phase I and II trials in various solid tumors. The cytotoxicity of CPT-11 on human ovarian epithelial malignancies was testedin vitroutilizing the ATP chemosensitivity assay. Flow cytometry was also performed on the fresh carcinoma specimens. Methods.Fresh tumor samples were obtained at laparotomy from 20 patients with primary adenocarcinoma of the ovary and 1 patient with heavily pretreated recurrent ovarian carcinoma. Tumors were plated in anin vitrosystem and treated with varying doses of both CPT-11 and its active metabolite SN-38 (7-ethyl-10-hydroxycamptothecin), in addition to a panel of standard chemotherapeutic agents used in treating ovarian cancer. On the sixth day after incubation, ATP levels in remaining cells were measured using a luminometer as an indication of the amount of cell kill compared to untreated controls. Results.Twelve of the 21 tumors were evaluable for a response to CPT-11. Of the 12 tumors tested, 7 were found to have median effect doses of CPT-11 significantly under the clinically achievable peak plasma concentration (range 1.00 × 10−4to 44.67 μM) and 11 of the 12 tumors showed sensitivity to the active metabolite SN38 with median effect doses ranging from 2.00 × 10−4to 0.147 μM. Some of these tumors showed resistance to the standard agents, such as platinum, based on our assay. The heavily pretreated recurrent tumor tested was very sensitive to both CPT-11 and SN38 by our assay. The results of flow cytometry showed that the tumors were composed of heterogeneous populations of cells with mean S phase fractions varying from 7.0 to 17.3%. The only tumor not sensitive to SN38 showed the highest mean S phase activity of 17.3%. Conclusions.Overall, these results suggest that CPT-11 deserves further investigation as a clinically useful chemotherapeutic agent for ovarian cancer." @default.
• W2067204905 created "2016-06-24" @default.
• W2067204905 creator A5021587183 @default.
• W2067204905 creator A5058542377 @default.
• W2067204905 date "1999-02-01" @default.
• W2067204905 modified "2023-10-18" @default.
• W2067204905 title "In VitroSensitivity of Fresh Ovarian Carcinoma Specimens to CPT-11 (Irinotecan)" @default.
• W2067204905 cites W1541845741 @default.
• W2067204905 cites W1774923611 @default.
• W2067204905 cites W1842750039 @default.
• W2067204905 cites W1897082568 @default.
• W2067204905 cites W1908304664 @default.
• W2067204905 cites W1972483602 @default.
• W2067204905 cites W1972513129 @default.
• W2067204905 cites W1974350050 @default.
• W2067204905 cites W1994031750 @default.
• W2067204905 cites W1997185869 @default.
• W2067204905 cites W2010991676 @default.
• W2067204905 cites W2011909208 @default.
• W2067204905 cites W2013124199 @default.
• W2067204905 cites W2032687836 @default.
• W2067204905 cites W2045773071 @default.
• W2067204905 cites W2048079370 @default.
• W2067204905 cites W2055625413 @default.
• W2067204905 cites W2065612477 @default.
• W2067204905 cites W2102803098 @default.
• W2067204905 cites W2151906733 @default.
• W2067204905 cites W2261826041 @default.
• W2067204905 cites W2399621825 @default.
• W2067204905 cites W2400318368 @default.
• W2067204905 cites W2416119952 @default.
• W2067204905 cites W2418676692 @default.
• W2067204905 cites W1715539307 @default.
• W2067204905 doi "https://doi.org/10.1006/gyno.1998.5241" @default.
• W2067204905 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10021292" @default.
• W2067204905 hasPublicationYear "1999" @default.
• W2067204905 type Work @default.
• W2067204905 sameAs 2067204905 @default.
• W2067204905 citedByCount "12" @default.
• W2067204905 countsByYear W20672049052014 @default.
• W2067204905 countsByYear W20672049052018 @default.
• W2067204905 crossrefType "journal-article" @default.
• W2067204905 hasAuthorship W2067204905A5021587183 @default.
• W2067204905 hasAuthorship W2067204905A5058542377 @default.
• W2067204905 hasConcept C121608353 @default.
• W2067204905 hasConcept C126322002 @default.
• W2067204905 hasConcept C142724271 @default.
• W2067204905 hasConcept C143998085 @default.
• W2067204905 hasConcept C147897179 @default.
• W2067204905 hasConcept C149151106 @default.
• W2067204905 hasConcept C202751555 @default.
• W2067204905 hasConcept C203014093 @default.
• W2067204905 hasConcept C2776694085 @default.
• W2067204905 hasConcept C2777477808 @default.
• W2067204905 hasConcept C2777546739 @default.
• W2067204905 hasConcept C2778324911 @default.
• W2067204905 hasConcept C2780259306 @default.
• W2067204905 hasConcept C2780427987 @default.
• W2067204905 hasConcept C2780508388 @default.
• W2067204905 hasConcept C2781182431 @default.
• W2067204905 hasConcept C3019054536 @default.
• W2067204905 hasConcept C502942594 @default.
• W2067204905 hasConcept C526805850 @default.
• W2067204905 hasConcept C553184892 @default.
• W2067204905 hasConcept C55493867 @default.
• W2067204905 hasConcept C71924100 @default.
• W2067204905 hasConcept C86803240 @default.
• W2067204905 hasConceptScore W2067204905C121608353 @default.
• W2067204905 hasConceptScore W2067204905C126322002 @default.
• W2067204905 hasConceptScore W2067204905C142724271 @default.
• W2067204905 hasConceptScore W2067204905C143998085 @default.
• W2067204905 hasConceptScore W2067204905C147897179 @default.
• W2067204905 hasConceptScore W2067204905C149151106 @default.
• W2067204905 hasConceptScore W2067204905C202751555 @default.
• W2067204905 hasConceptScore W2067204905C203014093 @default.
• W2067204905 hasConceptScore W2067204905C2776694085 @default.
• W2067204905 hasConceptScore W2067204905C2777477808 @default.
• W2067204905 hasConceptScore W2067204905C2777546739 @default.
• W2067204905 hasConceptScore W2067204905C2778324911 @default.
• W2067204905 hasConceptScore W2067204905C2780259306 @default.
• W2067204905 hasConceptScore W2067204905C2780427987 @default.
• W2067204905 hasConceptScore W2067204905C2780508388 @default.
• W2067204905 hasConceptScore W2067204905C2781182431 @default.
• W2067204905 hasConceptScore W2067204905C3019054536 @default.
• W2067204905 hasConceptScore W2067204905C502942594 @default.
• W2067204905 hasConceptScore W2067204905C526805850 @default.
• W2067204905 hasConceptScore W2067204905C553184892 @default.
• W2067204905 hasConceptScore W2067204905C55493867 @default.
• W2067204905 hasConceptScore W2067204905C71924100 @default.
• W2067204905 hasConceptScore W2067204905C86803240 @default.
• W2067204905 hasIssue "2" @default.
• W2067204905 hasLocation W20672049051 @default.
• W2067204905 hasLocation W20672049052 @default.
• W2067204905 hasOpenAccess W2067204905 @default.
• W2067204905 hasPrimaryLocation W20672049051 @default.
• W2067204905 hasRelatedWork W1521764325 @default.
• W2067204905 hasRelatedWork W2000366629 @default.
• W2067204905 hasRelatedWork W2006838800 @default.

• next